Mesoblast Limited (NASDAQ:MESO) shares are trading higher on Friday after the company announced that Ryoncil received a J-Code from the United States Medicare & Medicaid Services, streamlining billing and payment processes for the product.
What To Know: The new permanent J-Code, J3402, became active for billing and reimbursement on October 1, providing a standardized and specific billing pathway for Ryoncil through Medicaid. The designation facilitates reimbursement and broader patient access, while commercial payers typically look to permanent J-codes to update their coverage systems.
